West Pharmaceutical (WST) Fundamental Analysis: Revenue, Earnings & Valuation

8.50 / 10

Outperform

Fundamental analysis rates WST Outperform with an 8.5/10 score. Profit‑MV and Cash‑MV are bullish, delivering solid returns, while Asset‑MV is a drag. ROE, ROA, and annualized equity returns rank in the top quartile, indicating robust profitability and cash generation.

Analysis Checks(9/10)

ROA (%)

Value12.48

Score3/3

Weight10.53%

1M Return1.79%

Annualized return on equity (%)

Value16.85

Score3/3

Weight9.56%

1M Return1.64%

Profit-MV

Value0.26

Score2/3

Weight18.89%

1M Return3.26%

Cash-UP

Value0.10

Score3/3

Weight19.55%

1M Return3.34%

Annualized net profit margin on total assets (%)

Value12.48

Score3/3

Weight10.53%

1M Return1.79%

ROE (diluted) (%)

Value15.54

Score3/3

Weight8.01%

1M Return1.39%

Asset-MV

Value-0.55

Score0/3

Weight-15.14%

1M Return-3.34%

ROE (%)

Value16.85

Score3/3

Weight9.56%

1M Return1.64%

Cash-MV

Value-0.50

Score3/3

Weight16.39%

1M Return2.65%

Net profit / Total profit (%)

Value80.24

Score3/3

Weight12.12%

1M Return2.09%

Is WST undervalued or overvalued?

WST scores 8.50/10 on fundamentals and holds a Discounted valuation at present. Backed by its 16.85% ROE, 16.06% net margin, 35.81 P/E ratio, 5.57 P/B ratio, and 1.19% earnings growth, these metrics solidify its Outperform investment rating.